

Idiopathic Pulmonary Fibrosis (IPF)

**Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)**

**Trial Status**  
Completed

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT02598193 2015-003280-11  
MA29895

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This clinical study will evaluate the safety and tolerability of combination treatment of nintedanib and pirfenidone in participants with IPF. Eligible participants must have received pirfenidone for at least 16 weeks on a stable dose. Nintedanib will be added on Day 1 of the study as a combination treatment for IPF for 24 weeks.

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

**NCT02598193 2015-003280-11 MA29895**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 40 Years & ≤ 80 Years

**Healthy Volunteers**  
No